AstraZeneca (AZN) Stock Forecast & Price Target

£116.54

-66.00 (-0.56%)

(As of 09/27/2024 ET)

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
1

Hold
2

Buy
6

Based on 9 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a sell rating, 2 have given a hold rating, and 6 have given a buy rating for AZN.

Consensus Price Target

£101.62

According to the 9 analysts' twelve-month price targets for AstraZeneca, the average price target is £101.62. The highest price target for AZN is £150, while the lowest price target for AZN is GBX 74. The average price target represents a forecasted downside of -12.80% from the current price of £116.54.

Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

AZN Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	£101.62	£105.53	£121.57	£119.14
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

The True Potential for Civil War… (Ad)

Radical leftists mobilizing illegal immigrants, violence and looting, even marital law. 43% of respondents, for example, in a recent survey said they believe a civil war is “likely” in the next decade.

Click here.

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies
Consensus Rating Score	2.56	2.78
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent AZN News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	JPMorgan Chase & Co. 3 of 5 stars		Reiterated Rating	Overweight
9/3/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Reiterated Rating	Hold	£110	-16.62%
9/2/2024	Berenberg Bank 2 of 5 stars		Reiterated Rating	Buy	£150	+13.48%
7/25/2024	Shore Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
7/2/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold	GBX 71 ➝ GBX 74	-99.39%
5/28/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
Get the Latest News and Ratings for AZN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.
4/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	£125	+18.56%
2/12/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/12/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell	£107 ➝ GBX 9,900	+4.16%
9/25/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		£127 ➝ £129	+15.72%
4/11/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		£127 ➝ £119	+2.20%
2/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dominic Lunn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		£118	+3.60%
2/9/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keyur Parekh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		GBX 6,950	-37.65%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:37 PM ET.

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 11, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

AstraZeneca's stock has shown resilience, trading near its 52-week high of $87.68, indicating positive investor sentiment.
The company has a strong average rating of "Buy" from analysts, with an average target price of $89.75, suggesting growth potential.
AstraZeneca reported a solid quarterly revenue of $12.45 billion, beating analyst estimates, showcasing strong financial performance.
The recent dividend yield of 1.8% and a payout ratio of 48.04% offer investors a steady income stream.
AstraZeneca's focus on the discovery, development, and commercialization of prescription medicines positions it well in the biopharmaceutical industry.

AstraZeneca
Bear Case

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

Despite positive ratings, AstraZeneca's stock recently traded down 2.2%, indicating potential volatility in the market.
The company's P/E ratio of 42.02 and P/E/G ratio of 1.65 may suggest the stock is currently overvalued, posing a risk to investors.
AstraZeneca recently cut its dividend, which could impact investor confidence in the company's financial stability.
The beta of 0.47 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors.
AstraZeneca's debt-to-equity ratio of 0.69 may raise concerns about the company's leverage and financial health.

AZN Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is £101.62, with a high forecast of £150 and a low forecast of GBX 74.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.
: According to analysts, AstraZeneca's stock has a predicted downside of -12.80% based on their 12-month stock forecasts.
: AstraZeneca has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., and Shore Capital in the past 90 days.
: Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.56 while the average consensus rating score for "medical" companies is 2.78. Learn more on how AZN compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Don’t wait for FDA approval (Ad)

Don’t let Wall Street fool you. AI is not the only hot sector in the market. Biotech is on fire as well.

And I’ll tell you all about them in this video.

This page (LON:AZN) was last updated on 9/28/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

AstraZeneca (AZN) Stock Forecast & Price Target